Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Telix Pharmaceuticals announced the release of 41,698 ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of Lightpoint Medical and its SENSEI® radio-guided surgery business. This release, set for 17 September 2025, is in accordance with ASX Listing Rule 3.10A and may impact the company’s market operations by potentially increasing share liquidity and investor interest.
The most recent analyst rating on (AU:TLX) stock is a Hold with a A$16.50 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, United Kingdom, Brazil, Canada, Europe, and Japan. The company is dedicated to addressing significant unmet medical needs in oncology and rare diseases, with a portfolio of clinical and commercial stage products.
Average Trading Volume: 2,267,426
Technical Sentiment Signal: Sell
Current Market Cap: A$4.84B
Learn more about TLX stock on TipRanks’ Stock Analysis page.